HK1210154A1 - Highly selective c-met inhibitors as anticancer agents c-met - Google Patents
Highly selective c-met inhibitors as anticancer agents c-metInfo
- Publication number
- HK1210154A1 HK1210154A1 HK15110897.6A HK15110897A HK1210154A1 HK 1210154 A1 HK1210154 A1 HK 1210154A1 HK 15110897 A HK15110897 A HK 15110897A HK 1210154 A1 HK1210154 A1 HK 1210154A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- met
- anticancer agents
- highly selective
- inhibitors
- met inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103223591A CN103122000B (zh) | 2012-09-03 | 2012-09-03 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
PCT/CN2013/080598 WO2014032498A1 (fr) | 2012-09-03 | 2013-08-01 | Inhibiteurs hautement sélectifs de c-met utilisés comme agents anticancéreux |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210154A1 true HK1210154A1 (en) | 2016-04-15 |
Family
ID=48453178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110897.6A HK1210154A1 (en) | 2012-09-03 | 2015-11-04 | Highly selective c-met inhibitors as anticancer agents c-met |
Country Status (6)
Country | Link |
---|---|
US (1) | US9695175B2 (fr) |
EP (1) | EP2892904B1 (fr) |
JP (1) | JP6106899B2 (fr) |
CN (1) | CN103122000B (fr) |
HK (1) | HK1210154A1 (fr) |
WO (1) | WO2014032498A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105326793A (zh) * | 2014-08-06 | 2016-02-17 | 中美冠科生物技术(太仓)有限公司 | 一种包含c-Met激酶抑制剂的固体分散体及其制备方法和用途 |
CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
CN109206357A (zh) * | 2017-07-04 | 2019-01-15 | 浙江九洲药业股份有限公司 | 一种格列齐特中间体的通式化合物及其制备方法和应用 |
CN112424222A (zh) * | 2018-02-17 | 2021-02-26 | 冠科美博有限公司 | 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗 |
WO2020124060A1 (fr) * | 2018-12-14 | 2020-06-18 | Beta Pharma, Inc. | Composés substitués par organophosphoré en tant qu'inhibiteurs de c-met et leurs utilisations thérapeutiques |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
CN114599978A (zh) * | 2019-06-06 | 2022-06-07 | 浙江冠科美博生物科技有限公司 | 使用c-met抑制剂治疗癌症患者的方法 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US20230338294A1 (en) * | 2020-04-26 | 2023-10-26 | Apollomics Inc. | Novel pharmaceutical formulation for c-met inhibitor |
CN113105436B (zh) * | 2021-04-20 | 2022-07-01 | 西格莱(苏州)生物医药有限公司 | 吡唑类化合物的制备方法及其中间体 |
CN116283997A (zh) * | 2022-09-08 | 2023-06-23 | 药康众拓(江苏)医药科技有限公司 | 氘代hgfr抑制剂药物及用途 |
WO2024068947A1 (fr) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Dérivés de pyrazole microbiocides |
WO2024068950A1 (fr) | 2022-09-30 | 2024-04-04 | Syngenta Crop Protection Ag | Dérivés de pyrazole microbiocides |
WO2024115512A1 (fr) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Dérivés de tétrahydroisoquinoline microbiocides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101412675B1 (ko) * | 2005-12-21 | 2014-07-03 | 얀센 파마슈티카 엔.브이. | 티로신 키나제 모듈레이터로서의 트리아졸로피리다진 |
PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环三唑类化合物 |
KR101083177B1 (ko) * | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
DK2084162T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
PE20091468A1 (es) * | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
AR085183A1 (es) * | 2010-07-30 | 2013-09-18 | Lilly Co Eli | Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer |
-
2012
- 2012-09-03 CN CN2012103223591A patent/CN103122000B/zh active Active
-
2013
- 2013-08-01 US US14/424,395 patent/US9695175B2/en active Active
- 2013-08-01 WO PCT/CN2013/080598 patent/WO2014032498A1/fr active Application Filing
- 2013-08-01 EP EP13832587.3A patent/EP2892904B1/fr active Active
- 2013-08-01 JP JP2015528851A patent/JP6106899B2/ja active Active
-
2015
- 2015-11-04 HK HK15110897.6A patent/HK1210154A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2892904B1 (fr) | 2018-10-17 |
US20150218171A1 (en) | 2015-08-06 |
JP2015526486A (ja) | 2015-09-10 |
WO2014032498A1 (fr) | 2014-03-06 |
JP6106899B2 (ja) | 2017-04-05 |
CN103122000A (zh) | 2013-05-29 |
US9695175B2 (en) | 2017-07-04 |
EP2892904A1 (fr) | 2015-07-15 |
EP2892904A4 (fr) | 2016-04-06 |
CN103122000B (zh) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181849T1 (hr) | Triciklični spojevi kao antikancerogeni agensi | |
HK1210154A1 (en) | Highly selective c-met inhibitors as anticancer agents c-met | |
HK1212984A1 (zh) | 咪唑並吡啶化合物 | |
EP2814472A4 (fr) | Agents réducteurs dithioamine | |
EP2823830A4 (fr) | Agent d'élévation de la muqueuse | |
EP2864289A4 (fr) | Composés aromatiques cyclopropanecarboxamido-substitués utilisables en tant qu'agents anti-tumoraux | |
HK1203811A1 (en) | Anticancer agent | |
HK1202859A1 (en) | Anti -malarial agents | |
EP2842561A4 (fr) | Agent améliorant l'environnement entéral | |
ZA201408094B (en) | Anti-malarial agents | |
EP2804611A4 (fr) | Compositions dérivées du chitosane | |
GB201201287D0 (en) | Compositions | |
EP2837387A4 (fr) | Agent anticancéreux | |
EP2889035A4 (fr) | Agent anti-tumoral | |
SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
HUE045654T2 (hu) | Anyagkeverékek | |
ZA201400726B (en) | Anticancer agent | |
RS55201B1 (sr) | Antimalarijski agensi | |
EP2926813A4 (fr) | Compositions de métformine-orlistat | |
GB201208751D0 (en) | Anti-malarial compounds | |
GB201203082D0 (en) | Compositions | |
GB201203083D0 (en) | Compositions |